{"data":{"ModuleTitle":{"label":"Module Title","value":"Company Description"},"CompanyName":{"label":"Company Name","value":"Marinus Pharmaceuticals, Inc."},"Symbol":{"label":"Symbol","value":"MRNS"},"Address":{"label":"Address","value":"100 MATSONFORD ROAD,SUITE 500, 5 RADNOR CORPORATE CENTER, RADNOR, Pennsylvania, 19087, United States"},"Phone":{"label":"Phone","value":"+1 484 801-4670"},"Industry":{"label":"Industry","value":"Biotechnology: Pharmaceutical Preparations"},"Sector":{"label":"Sector","value":"Health Care"},"Region":{"label":"Region","value":"North America"},"CompanyDescription":{"label":"Company Description","value":"Marinus Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It is focused on developing and commercializing innovative therapeutics to treat epilepsy and neuropsychiatric disorders. Marinus manages the business in one segment, which is the identification and development of neuropsychiatric therapeutics. The Company is developing ganaxolone for multiple epilepsy and other neuropsychiatric indications, including adjunctive, or add-on, therapy for the treatment of drug-resistant focal onset seizures; status epilepticus; Fragile X Syndrome, and PCDH19 pediatric epilepsy."},"CompanyUrl":{"label":"Company Url","value":"https://www.marinuspharma.com"},"KeyExecutives":{"label":"Key Executives","value":[{"name":"Joseph Hulihan","title":"Chief Medical Officer"},{"name":"Michael S. Saporito","title":"Vice President-Research"},{"name":"Scott N. Braunstein","title":"Chairman, President & Chief Executive Officer"},{"name":"Steven E. Pfanstiel","title":"Chief Financial & Operating Officer, Treasurer"}]}},"message":null,"status":{"rCode":200,"bCodeMessage":null,"developerMessage":null}}